Depo-Estradiol Shortage Update: What Patients Need to Know in 2026

If you've been following news about hormone therapy availability, you already know 2026 has been a challenging year for estrogen medications. Depo-Estradiol (estradiol cypionate injection) is no exception. This article provides the most current update on Depo-Estradiol availability and what it means for patients who depend on it.

Current Status: What We Know as of 2026

Here is the current situation with Depo-Estradiol as of 2026:

Brand discontinued: Pfizer has discontinued the brand-name Depo-Estradiol product. It is no longer commercially manufactured and is not available through standard retail pharmacy supply chains.

Not on FDA shortage list: As of May 2026, estradiol cypionate injection is not on the FDA's official drug shortage list. However, this reflects the fact that the brand was proactively discontinued rather than disrupted unexpectedly.

Compounded versions available: Estradiol cypionate injection is available through 503A and 503B compounding pharmacies. These are the primary source for patients in 2026.

Patient reports of difficulty: Patients continue to report difficulty locating pharmacies that carry compounded estradiol cypionate, particularly in rural areas with fewer compounding pharmacies.

Why Was Depo-Estradiol Discontinued?

Pharmaceutical companies discontinue products for various reasons, including low commercial return relative to production costs, competition from generic equivalents, or strategic business decisions. Sterile injectable medications are expensive to manufacture due to the facility requirements, quality controls, and regulatory oversight involved. When a drug has a relatively small user base compared to larger blockbuster products, a company may decide it's not economically viable to continue production.

In the case of Depo-Estradiol, the estradiol cypionate market was likely deemed too small to justify continued commercial manufacturing, especially given the complexity of sterile injectable production. This is despite — or perhaps in the context of — growing demand from both the menopausal hormone therapy market and the gender-affirming care community.

The Broader 2026 Estrogen Shortage Context

The Depo-Estradiol discontinuation is part of a wider wave of estrogen supply challenges in 2026. Several factors are at play:

Demand explosion: Prescriptions for estrogen-based therapies among women aged 45-54 increased 184% between 2018 and 2026. Prescriptions surged an additional 20% between July 2025 and February 2026 alone.

FDA black box warning removal: In November 2025, the FDA removed the long-standing black box warning from bioidentical estradiol patches, gels, and creams — a warning that had overstated cardiovascular and cancer risks for younger menopausal women. This removal accelerated prescription growth.

Patch shortage ripple effect: The ongoing nationwide shortage of estradiol patches in 2026 is pushing some patients toward injectable estrogens, increasing demand for compounded estradiol cypionate.

Gender-affirming care growth: Demand for injectable estradiol from transgender patients has grown significantly, creating additional pressure on already limited supply.

What Does This Mean for Your Treatment?

If you are currently receiving Depo-Estradiol from your healthcare provider's office or a clinic, the situation may be different from patients who self-inject. Clinic settings often have access to a wider supplier network and may have stockpiled vials or established relationships with compounding pharmacies. If your clinic is concerned about supply, they will communicate this.

If you self-inject at home, you need to be proactive. Here is what you should do right now:

Contact your prescriber to confirm your prescription is updated for compounded estradiol cypionate.

Ask for a referral to a 503A or 503B compounding pharmacy in your area or one that ships nationally.

Discuss backup options — whether Delestrogen (estradiol valerate injection), estradiol gel, or oral estradiol — in case you cannot access compounded cypionate.

Never abruptly stop estrogen therapy without medical guidance — withdrawal can cause a rapid return of symptoms and may have health consequences with long-term use.

Is There Any Hope for Future Commercial Supply?

It's possible that a generic manufacturer could enter the market and produce commercially manufactured estradiol cypionate injection in the future, particularly given the growing demand. However, launching a sterile injectable manufacturing program takes years and significant capital investment. In the near term — through at least the end of 2026 — patients should plan for compounding pharmacies to remain their primary access point for estradiol cypionate.

How to Stay Updated

The best ways to stay informed about Depo-Estradiol availability include checking the medfinder shortage tracker for real-time pharmacy availability data, monitoring the FDA drug shortage database (fda.gov), and staying in touch with your prescriber. For background on why the situation developed, read our full explainer on why Depo-Estradiol is hard to find in 2026.